CN1833687A - Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage - Google Patents
Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage Download PDFInfo
- Publication number
- CN1833687A CN1833687A CN 200610037641 CN200610037641A CN1833687A CN 1833687 A CN1833687 A CN 1833687A CN 200610037641 CN200610037641 CN 200610037641 CN 200610037641 A CN200610037641 A CN 200610037641A CN 1833687 A CN1833687 A CN 1833687A
- Authority
- CN
- China
- Prior art keywords
- olibanum
- group
- radix
- chinese medicine
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 14
- 208000023652 chronic gastritis Diseases 0.000 title claims abstract description 13
- 208000025865 Ulcer Diseases 0.000 title description 31
- 231100000397 ulcer Toxicity 0.000 title description 31
- 230000001079 digestive effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 55
- 239000004863 Frankincense Substances 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 241000717739 Boswellia sacra Species 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 17
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000341 volatile oil Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 9
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 229940010454 licorice Drugs 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 238000010411 cooking Methods 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 8
- 201000005917 gastric ulcer Diseases 0.000 abstract description 8
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 7
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 3
- 244000170916 Paeonia officinalis Species 0.000 abstract description 3
- 235000003717 Boswellia sacra Nutrition 0.000 abstract description 2
- 240000007551 Boswellia serrata Species 0.000 abstract description 2
- 235000012035 Boswellia serrata Nutrition 0.000 abstract description 2
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 47
- 210000002784 stomach Anatomy 0.000 description 47
- 210000004369 blood Anatomy 0.000 description 44
- 230000002496 gastric effect Effects 0.000 description 27
- 241000700159 Rattus Species 0.000 description 25
- 229940079593 drug Drugs 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 230000036407 pain Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 11
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000004051 gastric juice Anatomy 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 206010000087 Abdominal pain upper Diseases 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 206010000269 abscess Diseases 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 210000001187 pylorus Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000004448 titration Methods 0.000 description 8
- 210000001835 viscera Anatomy 0.000 description 8
- 102000057297 Pepsin A Human genes 0.000 description 7
- 108090000284 Pepsin A Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 229940111202 pepsin Drugs 0.000 description 7
- 208000037920 primary disease Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002183 duodenal effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229940074869 marquis Drugs 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002417 xiphoid bone Anatomy 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 2
- 208000036495 Gastritis atrophic Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241001608538 Boswellia Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017815 Gastric perforation Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 101100489867 Mus musculus Got2 gene Proteins 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- 101000773128 Rattus norvegicus Thymidine phosphorylase Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000010106 huo luo xiao ling dan Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229910021424 microcrystalline silicon Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Group | Dosage (g/kg) | Ulcer index | Suppression ratio (%) |
Model group losec group SANJIU WEITAI group I group II group III group | - 3.3 6.7 0.75 1.5 3.0 | 4.9±0.3 1.5±1.9 ** 2.7±2.3 * 2.7±2.5 * 3.0±2.4 * 1.6±1.4 ** | - 69.4 44.9 44.9 38.8 67.3 |
Group | Dosage (g/kg) | Number of animals | Ulcer index (mm 2) | Ulcer healing rate (%) |
Model group losec group SANJIU WEITAI group I group II group III group | - 3.3 6.7 0.75 1.5 3.0 | 10 13 12 11 12 13 | 3.99±1.19 2.36±0.79 ** 3.10±0.59 2.75±0.79 * 2.94±0.51 * 2.76±0.67 * | - 40.9 22.3 31.6 25.4 30.8 |
Group | Dosage (g/kg) | PH value | Free acid (mEq/L) | Total acidity (mEq/L) | Total acid output (μ Eq/h) |
Model group losec group SANJIU WEITAI group | - 3.3 6.7 | 1.6±0.4(10) 2.4±1.0 *(10) 4.1±2.2 **(10) | 13.3±4.8(10) 6.8±2.9 **(10) 4.9±3.2 **(6) | 17.7±4.6(10) 12.0±3.0 **(10) 9.3±5.2 **(6) | 27.3±12.2(10) 10.6±3.5 **(10) 10.6±6.0 **(6) |
I group II group III group | 0.75 1.5 3.0 | 1.7±0.5(10) 1.6±0.3(10) 2.0±0.9(10) | 13.2±3.2(9) 13.1±3.1(10) 12.7±3.3(10) | 18.7±3.5(9) 19.5±3.1(10) 17.7±3.3(10) | 20.9±9.2(9) 22.9±8.3(10) 17.7±5.4 *(10) |
Group | Dosage (g/kg) | Gastric juice amount (ml) | Pepsin activity (active unit/ml) | The pepsin output (active unit/h) |
Model group losec group SANJIU WEITAI group I group II group III group | - 3.3 6.7 0.75 1.5 3.0 | 7.6±1.8(10) 4.5±1.2 **(10) 4.7±3.5 *(10) 5.0±2.5 *(10) 5.7±1.5 *(10) 5.1±1.7 **(10) | 426.1±136.0(10) 453.3±115.4(10) 327.3±245.9(10) 422.0±110.5(9) 514.9±95.6(10) 398.5±86.8(10) | 620.1±179.2(10) 389.8±88.9 **(10) 29.7±141.9 **(10) 476.0±249.8(9) 589.2±185.0(10) 393.4±105.2 *(10) |
Detect bacterial strain | MIC(mg/ml) | |
The strain of reference culture clinical isolates | ATCC-49503 virulent strain 01 virulent strain 02 avirulent strains 05 avirulent strains 06 | 12.50 18.75 25.00 12.50 12.50 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610037641XA CN100446787C (en) | 2006-01-09 | 2006-01-09 | Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610037641XA CN100446787C (en) | 2006-01-09 | 2006-01-09 | Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1833687A true CN1833687A (en) | 2006-09-20 |
CN100446787C CN100446787C (en) | 2008-12-31 |
Family
ID=37001677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200610037641XA Expired - Fee Related CN100446787C (en) | 2006-01-09 | 2006-01-09 | Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100446787C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104585282A (en) * | 2014-12-31 | 2015-05-06 | 无限极(中国)有限公司 | Biscuit and preparation method thereof |
CN106421897A (en) * | 2016-10-26 | 2017-02-22 | 曹京敏 | Human body soft tissue filling agent and preparation method thereof and specialized pulverizer |
CN107267288A (en) * | 2017-06-17 | 2017-10-20 | 安徽仁之堂药业有限公司 | A kind of highly effective extraction method of Olibanum volatile oil |
CN107890009A (en) * | 2017-11-25 | 2018-04-10 | 明光市绿园粮油贸易有限公司 | A kind of flour for treating chronic gastritis and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1218685A (en) * | 1998-10-30 | 1999-06-09 | 阎作礼 | Capsule for enterogastric disease |
CN100333772C (en) * | 2005-01-25 | 2007-08-29 | 蒋迎春 | Medicine for treating digestive tract ulcer and stomach cercinoma prophase pathologic change |
-
2006
- 2006-01-09 CN CNB200610037641XA patent/CN100446787C/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104585282A (en) * | 2014-12-31 | 2015-05-06 | 无限极(中国)有限公司 | Biscuit and preparation method thereof |
CN106421897A (en) * | 2016-10-26 | 2017-02-22 | 曹京敏 | Human body soft tissue filling agent and preparation method thereof and specialized pulverizer |
CN106421897B (en) * | 2016-10-26 | 2022-04-19 | 曹京敏 | Human soft tissue filler, preparation method thereof and special pulverizer |
CN107267288A (en) * | 2017-06-17 | 2017-10-20 | 安徽仁之堂药业有限公司 | A kind of highly effective extraction method of Olibanum volatile oil |
CN107890009A (en) * | 2017-11-25 | 2018-04-10 | 明光市绿园粮油贸易有限公司 | A kind of flour for treating chronic gastritis and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100446787C (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107753801A (en) | Anti-trioxypurine, drop purine treat pharmaceutical composition of gout and preparation method thereof | |
CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
CN104187172B (en) | Functional feed for treating enterogastritis diseases of turtles and preparation method of functional feed | |
CN100446787C (en) | Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage | |
CN1247231C (en) | Health care medicine for enriching blood in puerperium and its preparation and uses | |
CN105596994A (en) | Medicine for treating lung cancer cell proliferation | |
CN101780227A (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
BR112014030570B1 (en) | extracts of wild thyme and use of these | |
CN103405732B (en) | A kind of homogeneous design method for the treatment of Rotavirus Enteritis in Children and preparation method thereof | |
CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
CN104474103B (en) | A kind of natural plant hypoglycemic agent and preparation method thereof | |
CN103845450A (en) | Application of hawthorns in preparing medicine for treating hyperuricemia, gout and renal insufficiency | |
KR100712659B1 (en) | Herbal composition for treatment and prevention of diabetes and diabetic complications | |
CN1931262B (en) | Common cold treating Chinese medicine preparation | |
CN102198261A (en) | Chinese medicinal preparation for treating elder chronic colitis and preparation method thereof | |
CN101045116B (en) | Traditional Chinese medicine for treating cholecystitis | |
CN104013901A (en) | Medicament for treating pelvic inflammation | |
CN104306832A (en) | Chinese herba preparation for treating viral myocarditis and preparing method thereof | |
CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
CN103876207B (en) | Health soup for the treatment of tumor patient postoperative constipation and preparation method thereof | |
CN101890135B (en) | Antidepressant traditional Chinese medicine composition and application thereof | |
CN107184902B (en) | Traditional Chinese medicine composition for treating senile dementia | |
CN105497459A (en) | Traditional Chinese medicine preparation for treating woman leukorrheal diseases as well as preparation method and application of traditional Chinese medicine preparation | |
CN105596497A (en) | Pharmaceutical composition for treating pancreatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Diao Yong Document name: Notice of application for publication of patent for invention and entry into the substantive examination procedure |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Diao Yong Document name: Notice of application for publication of patent for invention and entry into the substantive examination procedure |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Nanjing Jianyou Biochemical Pharmaceutical Co.,Ltd. Assignor: NANJING EASEHEAL PHARMACEUTICAL CO.,LTD. Contract record no.: 2011320000103 Denomination of invention: Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage Granted publication date: 20081231 License type: Exclusive License Open date: 20060920 Record date: 20110228 |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20111206 Contract record no.: 2011320000103 Assignee after: Nanjing Kingfriend Biochemical Pharmaceutical Co.,Ltd. Assignee before: Nanjing Jianyou Biochemical Pharmaceutical Co.,Ltd. |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Nanjing Kingfriend Biochemical Pharmaceutical Co.,Ltd. Assignor: NANJING EASEHEAL PHARMACEUTICAL CO.,LTD. Contract record no.: 2011320000103 Date of cancellation: 20120827 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081231 |